The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | First line immunotherapy/chemotherapy in HER2- gastric cancer in Japan

Name: First line immunotherapy/chemotherapy in HER2- gastric cancer in Japan
Uploaded: 2020-07-02T00:00:00Z
Duration: 2 min 39 s
Description: Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, discusses first-line chemotherapy and immunotherapy in HER2-negative gastric cancer in Japan and the patients that benefit from either line of treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Kensei Yamaguchi • 2 Jul 2020

ESMO WCGIC 2020

Gastric Cancer Gastrointestinal Cancer Oxaliplatin TAS-118

SOLAR

Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, discusses first-line chemotherapy and immunotherapy in HER2-negative gastric cancer in Japan and the patients that benefit from either line of treatment. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).